Advanced Search: KEAP1/NRF2/NFELE2+

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.



A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line, Metastatic KEAP1/NRF2-mutated Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)